Cargando…

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer

OBJECTIVE: Cetuximab (Erbitux(®)) was approved for the treatment of metastatic colorectal cancer in Japan in 2008. To verify information on the safety in practical use of cetuximab, we conducted post-marketing surveillance in accordance with the conditions for approval. METHODS: All patients to be t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiguro, Megumi, Watanabe, Toshiaki, Yamaguchi, Kensei, Satoh, Taroh, Ito, Hideyuki, Seriu, Taku, Sakata, Yuh, Sugihara, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314322/ https://www.ncbi.nlm.nih.gov/pubmed/22327124 http://dx.doi.org/10.1093/jjco/hys005

Ejemplares similares

Severe Infusion Reactions to Cetuximab Occur within 1 h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Patients in Japan
por: Yamaguchi, Kensei, et al.
Publicado: (2014)

Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry
por: Satoh, Taroh, et al.
Publicado: (2014)

Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
por: Lee, Jung Eun, et al.
Publicado: (2008)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux(® )and particle therapy]
por: Jensen, Alexandra D, et al.
Publicado: (2011)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response
por: Bhuvaneswari, Ramaswamy, et al.
Publicado: (2009)

Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients(†)
por: Boku, Narikazu, et al.
Publicado: (2014)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
por: Watanabe, Toshiaki, et al.
Publicado: (2015)

Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial
por: Habl, G, et al.
Publicado: (2013)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
por: Watanabe, Toshiaki, et al.
Publicado: (2017)

1-year outcomes of patients implanted with the Perceval sutureless valve: the Japanese post-marketing surveillance study
por: Niinami, Hiroshi, et al.
Publicado: (2023)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study
por: Tamura, Mina, et al.
Publicado: (2022)

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
por: Uno, Shuji, et al.
Publicado: (2023)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
por: Baba, Hideo, et al.
Publicado: (2017)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial
por: Khan, Khurum, et al.
Publicado: (2016)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study
por: Sugiyama, Shigeru, et al.
Publicado: (2020)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
por: Hashiguchi, Yojiro, et al.
Publicado: (2019)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
por: Namba, Kenichi, et al.
Publicado: (2022)

Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer
por: MASUDA, TAIKI, et al.
Publicado: (2016)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)
por: Ishida, Hideyuki, et al.
Publicado: (2018)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Back reaction on the topological degrees of freedom in (1+2) dimensional spacetime
por: Seriu, M
Publicado: (1994)

The spectral representation of the spacetime structure: the "distance" between universe with different topologies
por: Seriu, M
Publicado: (1995)

Morphological Analyses of Colorectal Adenocarcinomas in Japanese Familial Adenomatous Polyposis Patients
por: Suzuki, Yozo, et al.
Publicado: (2022)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
por: Davari, Majid, et al.
Publicado: (2015)

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
por: Sato, Kazuo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pcksfdgs4ccmbpmd5jvhj191do